

Dmitry I Gabrilovich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2353108/publications.pdf>

Version: 2024-02-01

215
papers

59,179
citations

2797

94
h-index

1934

207
g-index

218
all docs

218
docs citations

218
times ranked

43305
citing authors

#	ARTICLE	IF	CITATIONS
1	Myeloid-derived suppressor cells as regulators of the immune system. <i>Nature Reviews Immunology</i> , 2009, 9, 162-174.	10.6	5,655
2	Understanding the tumor immune microenvironment (TIME) for effective therapy. <i>Nature Medicine</i> , 2018, 24, 541-550.	15.2	3,421
3	Coordinated regulation of myeloid cells by tumours. <i>Nature Reviews Immunology</i> , 2012, 12, 253-268.	10.6	3,002
4	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. <i>Nature Communications</i> , 2016, 7, 12150.	5.8	2,076
5	Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. <i>Nature Medicine</i> , 1996, 2, 1096-1103.	15.2	1,721
6	The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. <i>Trends in Immunology</i> , 2016, 37, 208-220.	2.9	1,507
7	Immunosuppressive Strategies that are Mediated by Tumor Cells. <i>Annual Review of Immunology</i> , 2007, 25, 267-296.	9.5	1,466
8	Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice. <i>Journal of Immunology</i> , 2008, 181, 5791-5802.	0.4	1,447
9	Myeloid-Derived Suppressor Cells. <i>Cancer Immunology Research</i> , 2017, 5, 3-8.	1.6	1,345
10	Myeloid-derived suppressor cells coming of age. <i>Nature Immunology</i> , 2018, 19, 108-119.	7.0	1,285
11	Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer. <i>Journal of Immunology</i> , 2001, 166, 678-689.	0.4	1,214
12	Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. <i>Nature Medicine</i> , 2004, 10, 48-54.	15.2	1,029
13	Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. <i>Nature Medicine</i> , 2007, 13, 828-835.	15.2	1,000
14	History of myeloid-derived suppressor cells. <i>Nature Reviews Cancer</i> , 2013, 13, 739-752.	12.8	974
15	HIF-1 α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. <i>Journal of Experimental Medicine</i> , 2010, 207, 2439-2453.	4.2	966
16	Mechanisms and functional significance of tumour-induced dendritic-cell defects. <i>Nature Reviews Immunology</i> , 2004, 4, 941-952.	10.6	920
17	Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo. <i>Blood</i> , 1998, 92, 4150-4166.	0.6	875
18	Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. <i>Journal of Clinical Investigation</i> , 2015, 125, 3356-3364.	3.9	846

#	ARTICLE	IF	CITATIONS
19	Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. <i>Journal of Experimental Medicine</i> , 2008, 205, 2235-2249.	4.2	796
20	Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. <i>Nature Reviews Immunology</i> , 2021, 21, 485-498.	10.6	755
21	Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species. <i>Journal of Immunology</i> , 2004, 172, 989-999.	0.4	742
22	Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. <i>Trends in Immunology</i> , 2011, 32, 19-25.	2.9	709
23	Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells. <i>Journal of Immunology</i> , 2009, 182, 5693-5701.	0.4	655
24	The Terminology Issue for Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2007, 67, 425-425.	0.4	649
25	MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis. <i>Journal of Experimental Medicine</i> , 2007, 204, 1463-1474.	4.2	581
26	Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. <i>Science Immunology</i> , 2016, 1, .	5.6	560
27	Lipid accumulation and dendritic cell dysfunction in cancer. <i>Nature Medicine</i> , 2010, 16, 880-886.	15.2	539
28	All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients. <i>Cancer Research</i> , 2006, 66, 9299-9307.	0.4	506
29	Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells. <i>Journal of Immunology</i> , 2001, 166, 5398-5406.	0.4	500
30	The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity. <i>European Journal of Immunology</i> , 2010, 40, 2969-2975.	1.6	497
31	VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. <i>Blood</i> , 2003, 101, 4878-4886.	0.6	465
32	Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. <i>Journal of Leukocyte Biology</i> , 2011, 91, 167-181.	1.5	457
33	Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. <i>Cancer Cell</i> , 2017, 32, 654-668.e5.	7.7	457
34	Fatty acid transport protein ² reprograms neutrophils in cancer. <i>Nature</i> , 2019, 569, 73-78.	18.7	440
35	Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer. <i>Journal of Immunology</i> , 2004, 172, 464-474.	0.4	418
36	Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 1111-1124.	3.9	406

#	ARTICLE	IF	CITATIONS
37	Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells. Annual Review of Medicine, 2015, 66, 97-110.	5.0	406
38	Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 878-887.	3.2	397
39	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
40	STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion. Journal of Immunology, 2005, 174, 4880-4891.	0.4	390
41	Mechanism of All-trans Retinoic Acid Effect on Tumor-Associated Myeloid-Derived Suppressor Cells. Cancer Research, 2007, 67, 11021-11028.	0.4	367
42	All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Research, 2003, 63, 4441-9.	0.4	350
43	Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells. Journal of Immunology, 2010, 184, 3106-3116.	0.4	342
44	Dendritic cells in cancer: the role revisited. Current Opinion in Immunology, 2017, 45, 43-51.	2.4	339
45	Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer. Cancer Immunology, Immunotherapy, 2006, 55, 237-245.	2.0	323
46	Rational design of shepherdin, a novel anticancer agent. Cancer Cell, 2005, 7, 457-468.	7.7	311
47	Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nature Immunology, 2013, 14, 211-220.	7.0	306
48	CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity, 2016, 44, 303-315.	6.6	299
49	Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nature Chemical Biology, 2020, 16, 278-290.	3.9	299
50	Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. Journal of Clinical Investigation, 2011, 121, 4015-4029.	3.9	298
51	Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells. Journal of Immunology, 2005, 175, 4583-4592.	0.4	297
52	Tumor Escape Mechanism Governed by Myeloid-Derived Suppressor Cells. Cancer Research, 2008, 68, 2561-2563.	0.4	292
53	Immature myeloid cells and cancer-associated immune suppression. Cancer Immunology, Immunotherapy, 2002, 51, 293-298.	2.0	289
54	Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 5187-5201.	3.2	288

#	ARTICLE	IF	CITATIONS
55	ER stress regulates myeloid-derived suppressor cell fate through TRAIL-mediated apoptosis. <i>Journal of Clinical Investigation</i> , 2014, 124, 2626-2639.	3.9	286
56	Plasticity of myeloid-derived suppressor cells in cancer. <i>Current Opinion in Immunology</i> , 2018, 51, 76-82.	2.4	281
57	Transcriptional regulation of myeloid-derived suppressor cells. <i>Journal of Leukocyte Biology</i> , 2015, 98, 913-922.	1.5	276
58	Regulation of Dendritic Cell Differentiation and Antitumor Immune Response in Cancer by Pharmacologic-Selective Inhibition of the Janus-Activated Kinase 2/Signal Transducers and Activators of Transcription 3 Pathway. <i>Cancer Research</i> , 2005, 65, 9525-9535.	0.4	273
59	Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. <i>Immunology</i> , 2014, 143, 512-519.	2.0	270
60	Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 909-918.	2.0	268
61	Induction of myelodysplasia by myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2013, 123, 4595-4611.	3.9	254
62	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. <i>Clinical Cancer Research</i> , 2018, 24, 5347-5356.	3.2	253
63	Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 1812-1823.	3.2	252
64	Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. <i>Blood</i> , 2004, 103, 3503-3510.	0.6	251
65	Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. <i>Journal of Leukocyte Biology</i> , 2003, 74, 186-196.	1.5	242
66	Dendritic Cells in Antitumor Immune Responses. <i>Cellular Immunology</i> , 1996, 170, 101-110.	1.4	230
67	Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells. <i>Seminars in Immunology</i> , 2018, 35, 19-28.	2.7	230
68	Notch-1 Regulates NF- κ B Activity in Hemopoietic Progenitor Cells. <i>Journal of Immunology</i> , 2001, 167, 4458-4467.	0.4	207
69	Myeloid-Derived Suppressor Cells in Human Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 348-353.	1.0	203
70	Oxidized Lipids Block Antigen Cross-Presentation by Dendritic Cells in Cancer. <i>Journal of Immunology</i> , 2014, 192, 2920-2931.	0.4	203
71	Dendritic Cells in Antitumor Immune Responses. <i>Cellular Immunology</i> , 1996, 170, 111-119.	1.4	199
72	Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. <i>Nature Communications</i> , 2017, 8, 2122.	5.8	196

#	ARTICLE	IF	CITATIONS
73	Activation of Dendritic Cells via Inhibition of Jak2/STAT3 Signaling. <i>Journal of Immunology</i> , 2005, 175, 4338-4346.	0.4	189
74	A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. <i>Nature Genetics</i> , 1996, 13, 210-213.	9.4	186
75	Phenotypic and Functional Analysis of Dendritic Cells and Clinical Outcome in Patients With High-Risk Melanoma Treated With Adjuvant Granulocyte Macrophage Colony-Stimulating Factor. <i>Journal of Clinical Oncology</i> , 2008, 26, 3235-3241.	0.8	178
76	Myeloid-Derived Suppressor Cells Regulate Growth of Multiple Myeloma by Inhibiting T Cells in Bone Marrow. <i>Journal of Immunology</i> , 2013, 190, 3815-3823.	0.4	176
77	Vascular Endothelial Growth Factor-Trap Overcomes Defects in Dendritic Cell Differentiation but Does Not Improve Antigen-Specific Immune Responses. <i>Clinical Cancer Research</i> , 2007, 13, 4840-4848.	3.2	171
78	Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. <i>Blood</i> , 2008, 111, 2220-2229.	0.6	171
79	Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. <i>Cancer and Metastasis Reviews</i> , 2006, 25, 323-331.	2.7	170
80	Reciprocal Relationship between Myeloid-Derived Suppressor Cells and T Cells. <i>Journal of Immunology</i> , 2013, 191, 17-23.	0.4	156
81	Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation. <i>Nature Medicine</i> , 2018, 24, 224-231.	15.2	150
82	Unique pattern of neutrophil migration and function during tumor progression. <i>Nature Immunology</i> , 2018, 19, 1236-1247.	7.0	140
83	Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody. <i>Clinical Cancer Research</i> , 2017, 23, 2942-2950.	3.2	137
84	Combination of γ -irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: Approach to treatment of advanced stage cancer. <i>International Journal of Cancer</i> , 2001, 94, 825-833.	2.3	128
85	Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	123
86	Consensus nomenclature for CD8 ⁺ T cell phenotypes in cancer. <i>Oncolmmunology</i> , 2015, 4, e998538.	2.1	119
87	A neuronal network of mitochondrial dynamics regulates metastasis. <i>Nature Communications</i> , 2016, 7, 13730.	5.8	112
88	Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. <i>Laboratory Investigation</i> , 2011, 91, 598-608.	1.7	111
89	Combination of External Beam Radiotherapy (EBRT) With Intratumoral Injection of Dendritic Cells as Neo-Adjuvant Treatment of High-Risk Soft Tissue Sarcoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 924-932.	0.4	109
90	INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 983-991.	1.4	107

#	ARTICLE	IF	CITATIONS
91	Molecular Pathways: Tumor-Infiltrating Myeloid Cells and Reactive Oxygen Species in Regulation of Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2012, 18, 4877-4882.	3.2	107
92	Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	107
93	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. <i>Nature Communications</i> , 2021, 12, 346.	5.8	107
94	GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. <i>Blood</i> , 2015, 126, 1621-1628.	0.6	104
95	^{63}Ni -driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 5095-5109.	3.9	102
96	Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer. <i>Cell Reports</i> , 2020, 33, 108571.	2.9	99
97	Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. <i>Molecular Immunology</i> , 2015, 63, 579-585.	1.0	98
98	Antigen-Specific CD4+ T Cells Regulate Function of Myeloid-Derived Suppressor Cells in Cancer via Retrograde MHC Class II Signaling. <i>Cancer Research</i> , 2012, 72, 928-938.	0.4	96
99	Notch and Wingless Signaling Cooperate in Regulation of Dendritic Cell Differentiation. <i>Immunity</i> , 2009, 30, 845-859.	6.6	95
100	Highlights of 10 years of immunology in <i>Nature Reviews Immunology</i> . <i>Nature Reviews Immunology</i> , 2011, 11, 693-702.	10.6	95
101	Myeloid-Derived Suppressor Cells in the Development of Lung Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 50-58.	1.6	95
102	Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic. <i>Cancer Discovery</i> , 2021, 11, 2693-2706.	7.7	89
103	HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. <i>Cancer Research</i> , 2019, 79, 5482-5489.	0.4	86
104	Notch signaling is necessary but not sufficient for differentiation of dendritic cells. <i>Blood</i> , 2003, 102, 3980-3988.	0.6	85
105	Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. <i>Journal of Experimental Medicine</i> , 2019, 216, 2150-2169.	4.2	85
106	The Ratio of Peripheral Regulatory T Cells to Lox-1 ⁺ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 243-246.	2.5	85
107	BTN3A1 governs antitumor responses by coordinating $\text{Î}1^2$ and $\text{Î}3^1$ T cells. <i>Science</i> , 2020, 369, 942-949.	6.0	83
108	Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. <i>Clinical Cancer Research</i> , 2003, 9, 285-94.	3.2	83

#	ARTICLE	IF	CITATIONS
109	Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy. <i>Cancer Research</i> , 2012, 72, 5483-5493.	0.4	81
110	Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 405-410.	2.0	81
111	Effects of Notch Signaling on Regulation of Myeloid Cell Differentiation in Cancer. <i>Cancer Research</i> , 2014, 74, 141-152.	0.4	80
112	Genetic Immunotherapy of Established Tumors with Adenovirus-Murine Granulocyte-Macrophage Colony-Stimulating Factor. <i>Human Gene Therapy</i> , 1997, 8, 187-193.	1.4	78
113	Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34+ progenitor cells. <i>Human Immunology</i> , 2001, 62, 332-341.	1.2	78
114	Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands. <i>Blood</i> , 2007, 109, 507-515.	0.6	78
115	Full-length dominant-negative survivin for cancer immunotherapy. <i>Clinical Cancer Research</i> , 2003, 9, 6523-33.	3.2	78
116	Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. <i>Cancer Discovery</i> , 2020, 10, 1282-1295.	7.7	75
117	Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer. <i>JCI Insight</i> , 2020, 5, .	2.3	72
118	Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. <i>Lancet Oncology</i> , The, 2007, 8, 2-3.	5.1	69
119	Tumor Escape from Immune Response: Mechanisms and Targets of Activity. <i>Current Drug Targets</i> , 2003, 4, 525-536.	1.0	67
120	Combined modality immunotherapy and chemotherapy: a new perspective. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1523-1529.	2.0	67
121	EGR1 is a gatekeeper of inflammatory enhancers in human macrophages. <i>Science Advances</i> , 2021, 7, .	4.7	67
122	Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells. <i>Seminars in Cancer Biology</i> , 2012, 22, 282-288.	4.3	65
123	Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells. <i>Journal of Experimental Medicine</i> , 2015, 212, 351-367.	4.2	65
124	ICAM-1 controls development and function of ILC2. <i>Journal of Experimental Medicine</i> , 2018, 215, 2157-2174.	4.2	62
125	Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 692-702.	2.0	61
126	Induction of Potent Human Immunodeficiency Virus Type 1-Specific T-Cell-Restricted Immunity by Genetically Modified Dendritic Cells. <i>Journal of Virology</i> , 2001, 75, 7621-7628.	1.5	60

#	ARTICLE	IF	CITATIONS
127	Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. <i>Cancer Letters</i> , 2016, 371, 117-124.	3.2	59
128	Lactoferrin-induced myeloid-derived suppressor cell therapy attenuates pathologic inflammatory conditions in newborn mice. <i>Journal of Clinical Investigation</i> , 2019, 129, 4261-4275.	3.9	59
129	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD(L)1 Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 1019-1028.	3.2	58
130	Structural and functional analysis of \hat{I}^{22} microglobulin abnormalities in human lung and breast cancer. , 1996, 67, 756-763.		57
131	INGN 201 (Advexin [®]): adenoviral p53 gene therapy for cancer. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 823-832.	1.4	56
132	Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 419-423.	2.0	56
133	CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. <i>JCI Insight</i> , 2018, 3, .	2.3	56
134	Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway. <i>Nature Communications</i> , 2021, 12, 1717.	5.8	53
135	Regulation of dendritic cell differentiation and function by Notch and Wnt pathways. <i>Immunological Reviews</i> , 2010, 234, 105-119.	2.8	52
136	Targeting of Jak/STAT Pathway in Antigen Presenting Cells in Cancer. <i>Current Cancer Drug Targets</i> , 2007, 7, 71-77.	0.8	48
137	Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements. <i>Cancer Research</i> , 2018, 78, 4215-4228.	0.4	47
138	Upregulation of C/EBP β Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5961-5978.	3.2	47
139	Phosphorylation of IRE1 at S729 regulates RIDD in B cells and antibody production after immunization. <i>Journal of Cell Biology</i> , 2018, 217, 1739-1755.	2.3	46
140	Tumor-Induced STAT3 Signaling in Myeloid Cells Impairs Dendritic Cell Generation by Decreasing PKC δ Abundance. <i>Science Signaling</i> , 2014, 7, ra16.	1.6	45
141	Notch signaling in differentiation and function of dendritic cells. <i>Immunologic Research</i> , 2008, 41, 1-14.	1.3	44
142	PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma. <i>JCI Insight</i> , 2020, 5, .	2.3	44
143	Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor. <i>Clinical and Experimental Metastasis</i> , 1999, 17, 881-888.	1.7	43
144	Developing dendritic cells become 'lacy' cells packed with fat and glycogen. <i>Immunology</i> , 2005, 115, 473-483.	2.0	42

#	ARTICLE	IF	CITATIONS
145	Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	41
146	Changes in Dendritic Cell Phenotype After a New High-dose Weekly Schedule of Interleukin-2 Therapy for Kidney Cancer and Melanoma. <i>Journal of Immunotherapy</i> , 2010, 33, 817-827.	1.2	40
147	Combined Inhibition of Notch Signaling and Bcl-2/Bcl-xL Results in Synergistic Antimyeloma Effect. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 3200-3209.	1.9	40
148	Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1009-1021.	2.0	40
149	Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice. <i>Cancer Research</i> , 2018, 78, 5644-5655.	0.4	40
150	Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 517-527.	2.0	39
151	Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1929-1936.	2.0	39
152	H1(0) histone and differentiation of dendritic cells. A molecular target for tumor-derived factors. <i>Journal of Leukocyte Biology</i> , 2002, 72, 285-96.	1.5	38
153	Syntaxilin controls a mitochondrial rheostat for proliferation-motility decisions in cancer. <i>Journal of Clinical Investigation</i> , 2017, 127, 3755-3769.	3.9	37
154	Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4239-4250.	1.0	36
155	“Redox lipidomics technology: Looking for a needle in a haystack” <i>Chemistry and Physics of Lipids</i> , 2019, 221, 93-107.	1.5	35
156	MFF Regulation of Mitochondrial Cell Death Is a Therapeutic Target in Cancer. <i>Cancer Research</i> , 2019, 79, 6215-6226.	0.4	34
157	Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. <i>Immunotherapy</i> , 2012, 4, 373-382.	1.0	33
158	“Only a Life Lived for Others Is Worth Living” Redox Signaling by Oxygenated Phospholipids in Cell Fate Decisions. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 1333-1358.	2.5	33
159	Activation of p38 β stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs. <i>Nature Cancer</i> , 2020, 1, 603-619.	5.7	33
160	ICAM-1 Deficiency in the Bone Marrow Niche Impairs Quiescence and Repopulation of Hematopoietic Stem Cells. <i>Stem Cell Reports</i> , 2018, 11, 258-273.	2.3	32
161	Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype. <i>iScience</i> , 2021, 24, 102016.	1.9	32
162	Myeloid-Derived Suppressor Cells and Radiotherapy. <i>Cancer Immunology Research</i> , 2022, 10, 545-557.	1.6	32

#	ARTICLE	IF	CITATIONS
163	Myc Regulation of a Mitochondrial Trafficking Network Mediates Tumor Cell Invasion and Metastasis. <i>Molecular and Cellular Biology</i> , 2019, 39, .	1.1	31
164	Transcriptional factor ATF3 protects against colitis by regulating follicular helper T cells in Peyer's patches. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 6286-6291.	3.3	30
165	Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies. <i>Drug Resistance Updates</i> , 2008, 11, 210-218.	6.5	27
166	Molecular speciation and dynamics of oxidized triacylglycerols in lipid droplets: Mass spectrometry and coarse-grained simulations. <i>Free Radical Biology and Medicine</i> , 2014, 76, 53-60.	1.3	26
167	Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus. <i>Journal of Clinical Investigation</i> , 2020, 130, 2789-2799.	3.9	26
168	Clinical Significance of Neutrophil Functional Activity in HIV Infection. <i>Scandinavian Journal of Infectious Diseases</i> , 1994, 26, 41-47.	1.5	25
169	Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 573-579.	2.0	25
170	Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth. <i>Journal of Biological Chemistry</i> , 2019, 294, 10407-10414.	1.6	25
171	BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. <i>Clinical Cancer Research</i> , 2019, 25, 2783-2794.	3.2	25
172	Murine Retrovirus Induces Defects in the Function of Dendritic Cells at Early Stages of Infection. <i>Cellular Immunology</i> , 1994, 158, 167-181.	1.4	23
173	Dendritic cell vaccines for cancer treatment. <i>Current Opinion in Molecular Therapeutics</i> , 2002, 4, 452-8.	2.8	23
174	Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice. <i>Cancer Immunology Research</i> , 2018, 6, 696-710.	1.6	21
175	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. <i>Nature Communications</i> , 2021, 12, 6023.	5.8	21
176	ROR1C Regulates Differentiation of Myeloid-Derived Suppressor Cells. <i>Cancer Cell</i> , 2015, 28, 147-149.	7.7	20
177	COX-1-derived thromboxane A2 plays an essential role in early B-cell development via regulation of JAK/STAT5 signaling in mouse. <i>Blood</i> , 2014, 124, 1610-1621.	0.6	18
178	Molecular mechanisms and therapeutic reversal of immune suppression in cancer. <i>Current Cancer Drug Targets</i> , 2007, 7, 1.	0.8	18
179	Immune Tolerance in Breast Cancer. <i>Breast Disease</i> , 2004, 20, 93-103.	0.4	16
180	Regulation of Dendritic Cell Differentiation in Bone Marrow during Emergency Myelopoiesis. <i>Journal of Immunology</i> , 2013, 191, 1916-1926.	0.4	16

#	ARTICLE	IF	CITATIONS
181	Regulation of plasmacytoid dendritic cell development in mice by aryl hydrocarbon receptor. <i>Immunology and Cell Biology</i> , 2014, 92, 200-203.	1.0	16
182	Mass-spectrometric characterization of peroxidized and hydrolyzed lipids in plasma and dendritic cells of tumor-bearing animals. <i>Biochemical and Biophysical Research Communications</i> , 2011, 413, 149-153.	1.0	15
183	A Novel Inhibitor of HSP70 Induces Mitochondrial Toxicity and Immune Cell Recruitment in Tumors. <i>Cancer Research</i> , 2020, 80, 5270-5281.	0.4	15
184	Myeloid-Derived Suppressor Cells Are a Major Source of Wnt5A in the Melanoma Microenvironment and Depend on Wnt5A for Full Suppressive Activity. <i>Cancer Research</i> , 2021, 81, 658-670.	0.4	15
185	Cellular immunotherapy for soft tissue sarcomas. <i>Immunotherapy</i> , 2012, 4, 283-290.	1.0	14
186	Myeloid Cell-Derived Oxidized Lipids and Regulation of the Tumor Microenvironment. <i>Cancer Research</i> , 2022, 82, 187-194.	0.4	14
187	The Dawn of Myeloid-Derived Suppressor Cells: Identification of Arginase I as the Mechanism of Immune Suppression. <i>Cancer Research</i> , 2021, 81, 3953-3955.	0.4	12
188	Effects of murine leukemia viruses on the function of dendritic cells. <i>European Journal of Immunology</i> , 1993, 23, 2932-2938.	1.6	11
189	The role of mannose-6-phosphate receptor and autophagy in influencing the outcome of combination therapy. <i>Autophagy</i> , 2013, 9, 615-616.	4.3	11
190	New roles of Rb1 in expansion of MDSCs in cancer. <i>Cell Cycle</i> , 2013, 12, 1329-1330.	1.3	10
191	Can the Suppressive Activity of Myeloid-Derived Suppressor Cells Be "Chopped"? <i>Immunity</i> , 2014, 41, 341-342.	6.6	10
192	All Myeloid-Derived Suppressor Cells Are Not Created Equal: How Gender Inequality Influences These Cells and Affects Cancer Therapy. <i>Cancer Discovery</i> , 2020, 10, 1100-1102.	7.7	7
193	Comment on "Cutting Edge: Induction of B7-H4 on APCs through IL-10: Novel Suppressive Mode for Regulatory T Cells". <i>Journal of Immunology</i> , 2007, 178, 4705.2-4706.	0.4	6
194	Editorial: The intricacy of choice: can bacteria decide what type of myeloid cells to stimulate?. <i>Journal of Leukocyte Biology</i> , 2014, 96, 671-674.	1.5	6
195	Myeloid-Derived Suppressor Cells (MDSC) Are Effectors of Bone Marrow Suppression in Lower Risk Myelodysplastic Syndromes (MDS).. <i>Blood</i> , 2009, 114, 597-597.	0.6	6
196	Microenvironment Induced Myelodysplastic Syndrome (MDS) in S100A9 Transgenic Mice Caused by Myeloid-Derived Suppressor Cells (MDSC). <i>Blood</i> , 2011, 118, 788-788.	0.6	6
197	β 1 integrin- and JNK-dependent tumor growth upon hypofractionated radiation. <i>Oncotarget</i> , 2016, 7, 52618-52630.	0.8	6
198	A Bayesian pick-the-winner design in a randomized phase II clinical trial. <i>Oncotarget</i> , 2017, 8, 88376-88385.	0.8	6

#	ARTICLE	IF	CITATIONS
199	ONP-302 Nanoparticles Inhibit Tumor Growth By Altering Tumor-Associated Macrophages And Cancer-Associated Fibroblasts. <i>Journal of Cancer</i> , 2022, 13, 1933-1944.	1.2	6
200	Detecting Prostate Cancer Using Pattern Recognition Neural Networks With Flow Cytometry-Based Immunophenotyping in At-Risk Men. <i>Biomarker Insights</i> , 2020, 15, 117727192091332.	1.0	5
201	Development of vaccines against self-antigens: the p53 paradigm. <i>Current Opinion in Drug Discovery & Development</i> , 2003, 6, 169-73.	1.9	5
202	Isolation and Phenotyping of Splenic Myeloid-Derived Suppressor Cells in Murine Cancer Models. <i>Methods in Molecular Biology</i> , 2021, 2236, 19-28.	0.4	4
203	Fatal attraction: How macrophages participate in tumor metastases. <i>Journal of Experimental Medicine</i> , 2015, 212, 976-976.	4.2	3
204	A Novel Agent Tasquinimod Demonstrates a Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma. <i>Blood</i> , 2014, 124, 5729-5729.	0.6	3
205	Applying Pressure on Macrophages. <i>Immunity</i> , 2013, 38, 205-206.	6.6	2
206	Biology of Myeloid-Derived Suppressor Cells. , 2018, , 181-197.		2
207	Recent Advances in Immunotherapy of Lung Cancer. <i>Journal of Lung Cancer</i> , 2012, 11, 1.	0.2	1
208	Mechanisms regulating transitory suppressive activity of neutrophils in newborns: PMNsâ€MDSCs in newborns. <i>Journal of Leukocyte Biology</i> , 0, , .	1.5	1
209	M17-02: Immunotherapy of extensive stage small cell lung cancer with dendritic cell based p53 vaccine. <i>Journal of Thoracic Oncology</i> , 2007, 2, S198-S199.	0.5	0
210	Editorial overview: Many shades of grey: how immune response is regulated by tumors. <i>Current Opinion in Immunology</i> , 2017, 45, ix-xi.	2.4	0
211	A New Target in Multiple Myeloma: Inhibition of Notch Pathway Induces Apoptosis and Enhances Drug Sensitivity of Myeloma Cells In Vitro and In Vivo.. <i>Blood</i> , 2006, 108, 841-841.	0.6	0
212	Significant Expansion of Myeloid Derived Suppressor Cells in Patients with High- Risk Breast Cancer Treated with Dose Dense Adjuvant Chemotherapy. <i>Blood</i> , 2008, 112, 4653-4653.	0.6	0
213	Novel Role of Histone Deacetylase 11 (HDAC11) in Hematopoiesis. <i>Blood</i> , 2012, 120, 4728-4728.	0.6	0
214	Accumulation of Myeloid-Derived Suppressor Cells in Bone Marrow in Multiple Myeloma Induces Tumor-Specific Immune Suppression and Promotes Tumor Growth. <i>Blood</i> , 2012, 120, 3954-3954.	0.6	0
215	Dynamic Changes and Impact of Myeloid Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice.. <i>Blood</i> , 2012, 120, 2999-2999.	0.6	0